Previous 10 | Next 10 |
Royalty Pharma plc (RPRX) Q3 2021 Results Conference Call November 10, 2021 8:00 AM ET Company Participants Pablo Legorreta – Founder and Chief Executive Officer Chris Hite – Vice Chairman Terry Coyne – EVP, Chief Financial Officer Jim Reddoch – EVP, Co-Head of Res...
Net cash provided from operating activities (GAAP) of $470 million; Adjusted Cash Receipts ( 1) (non-GAAP) of $587 million and Adjusted Cash Flow (2) (non-GAAP) of $441 million Announced transactions of up to $2.8 billion in 2021, including $2.1 b...
Royalty Pharma (NASDAQ:RPRX) is scheduled to announce Q3 earnings results on Wednesday, November 10th, before market open. The consensus EPS Estimate is $0.70 and the consensus Revenue Estimate is $573.8M (+6.7% Y/Y). Over the last 3 months, EPS estimates have seen 6 upward revisions and 0 do...
RPRX buys royalties of high-profile assets. It has been in business for over 20 years. The MorphoSys M&A deal opens up a new business angle for the company. For further details see: Royalty Pharma Provides Unique Diversity To A Biopharma Portfolio
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webc...
NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share. The dividend will be paid on December 15, 2021, to shareholders of record ...
With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a decline in their stock prices. Regeneron Pharmaceuticals Regeneron Pharmaceut...
The pharmaceutical market reached a total value of US$1.27 trillion in 2020, according to data from Statista , up significantly from US$887 billion in 2010. By 2025, that value is expected to increase even further to an estimated US$1.6 billion. Experienced and novice invest...
Image source: The Motley Fool. Royal Pharma (NASDAQ: RPRX) Q2 2021 Earnings Call Aug 11, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Royal Pharma (RPRX) Q2 2021 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q2 2021 Earnings Conference Call August 11, 2021, 8:00 am ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder & CEO Jim Reddoch - EVP, Co-Head Research & Investments & CSO Marshall Urist - EVP & Co...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...